Skip to main content
Premium Trial:

Request an Annual Quote

Claremont BioSolutions, Funakoshi Reach Distribution Deal for Japan

NEW YORK (GenomeWeb News) – Claremont BioSolutions today said Funakoshi will distribute its sample preparation, DNA isolation, and protein purification products in Japan.

Funakoshi will offer Claremont's products to various customers in the academic and bioscience community, Claremont said, adding the agreement is part of its strategy to expand its footprint in Asia and Europe. The Upland, Calif.-based company reached a distribution deal with Bioquote earlier this month for the UK and Ireland.

Claremont develops, manufactures, and markets cell lysis, DNA extraction, and His-tagged protein purification kits and columns. Its first commercially marketed products are its Omnilyse lysis kits and PureLyse extraction kits.

Terms of today's deal were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.